Clinical Trial Update: Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis [Phase 1]

View source ↗

Summary

Open-label Phase I single-dose pharmacokinetics and safety study of BI 201335 in patients with compensated liver cirrhosis and Hepatitis C; the trial is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Cirrhosis

Drugs mentioned

• BI 201335

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C, Liver Cirrhosis | Phase 1 | Status: COMPLETED | Results posted: 2015-08-10